McKesson Corporation vs ON Holding AG — how do they compare? McKesson Corporation trades at $937.1 (market cap $108.46B), while ON Holding AG trades at $35.05 (market cap $11.38B). The key difference: McKesson Corporation is far larger — about 9.5× ON Holding AG's market cap, and McKesson Corporation pays a 0.4% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and ON Holding AG for 22 Days on average.
| MCK | ONON | |
|---|---|---|
Market Cap | $108.46B | $11.38B |
Volume | 712,607 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $50.63 |
52-Week Low | $725.17 | $26.76 |
Typical Hold Time | 74 Days | 22 Days |
Enterprise Value | $115.00B | $10.54B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $938.84, up 3.13% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
The outlook is positive with 81% analyst buy ratings and a $956.43 consensus price target. Key risks include margin pressure from drug pricing policies and high current liabilities of $61.60B. The stock's valuation at 24.95x P/E appears reasonable given earnings growth projections, but investors should monitor debt levels and regulatory developments in healthcare distribution.
ONON trades at $34.99, up 5.33% with strong bullish momentum. The stock shows robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 beating expectations of $0.42. Technical indicators show bullish moving averages but overbought RSI conditions. Recent investor day announcements of a $1 billion buyback and ambitious 2029 targets have driven positive sentiment.
Outlook remains positive with analyst consensus at $42.26 target (21% upside) and 74% buy ratings. Key opportunities include DTC growth and margin expansion, while risks include execution on growth targets and competitive pressures in the athletic footwear sector. The stock trades at reasonable valuations with P/E of 24.02 and EV/EBITDA of 14.79.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →